The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
the problem when it comes to gero protection this broad category where we are not targeting diseases specifically but instead we're targeting the underlying mechanisms of Aging is we can't measure it we don't have a way to measure it we really don't have biomarkers for aging
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
you have to trust the biomarker of aging rate before you can be confident that the drug that moves the biomarker of aging rate works in people
a biomarker allegedly and in real life uh is something that changes with age so if you have some drug that slows aging the biomarkers many of them in the different cell types and in the blood will change more slow slowly they are a good way of looking at whether you're slowing it'll work in the dogs long long lived dogs and shortlived dogs will have differences in the rate of change of biomarkers very established part of the literature and valuable but you have to wait till somebody's old whether it's a dog or a mouse or a person because only when they're old has the biomarker of Aging the surrogate marker for biological aging changed very much
when we study blood pressure drugs or cholesterol drugs the biomarkers change so rapidly and we know the relationship between the biomarker and the disease state so if your blood pressure is 145 over 90 on average before I give you this ACE inhibitor and 3 months later 6 months later n9ine months later a year later your blood pressure is averaging 119 over 74 I know I've done something well now I will still probably in the phase three in fact I will in the phase three have to make sure that I also reduce some event in you but generally by the phase two I know that this drug is not toxic and that it's predictably lowering your blood pressure that's that's really really valuable a biomarker generically is something that's easy to measure that you is informative about something that's hard to measure
So, I think this brings out one of the key things that is lacking in the field of aging, is the identification of biomarkers that would allow us to test on an individual basis whether the intervention or the modifications that you’re imposing is actually pointing you in the right direction or in the wrong direction.